Last updated 2026-06-18
- Raised funding round, Nov 2019
Total raised
—
Last: 2019-11
Stage
Seed
Founded
2019
Headcount
6
HQ
, Israel
Sector
Health Tech & Life Sciences
About
Nevrox is a drug discovery company developing a neuroprotective small molecule modulator of protein disulfide isomerase (PDI) for the treatment of Huntingtons disease (HD) and amyotrophic lateral sclerosis (ALS). The company is part of the FuturX biotech incubator in Ness Ziona.
Funding history · 1 round · — total
2019-11
Undisclosed
Q&A
- What is Nevrox's primary focus?
- Nevrox is a drug discovery company developing a neuroprotective small molecule modulator of protein disulfide isomerase (PDI) for the treatment of Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
- When was Nevrox founded?
- Nevrox was founded in July 2019.
- What is the current status of Nevrox?
- Nevrox is currently inactive, having ceased operations in September 2022.
- Which investors participated in Nevrox's funding round?
- In November 2019, Nevrox received funding from RMGP Biopharma Investment Fund and FutuRx.
- What is Nevrox's current stage?
- Nevrox's current stage is Seed.
- Where is Nevrox headquartered?
- Nevrox is headquartered in Ness Ziyyona, Israel.
- What sector does Nevrox operate in?
- Nevrox operates in the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Team · 2
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
degenerative-diseasestreatmentsbiotechnologyneurologypharmaceuticalsdrug-discoverypharma-companiesamyotrophic-lateral-sclerosis-als
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2019-7 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Sep 2022 ceased to operate |